Nalaganje...
Etrolizumab for the Treatment of Ulcerative Colitis and Crohn’s Disease: An Overview of the Phase 3 Clinical Program
INTRODUCTION: Etrolizumab is a next-generation anti-integrin with dual action that targets two pathways of inflammation in the gut. A robust phase 3 clinical program in ulcerative colitis (UC) and Crohn’s disease is ongoing and will evaluate the efficacy and safety of etrolizumab in well-defined pat...
Shranjeno v:
| izdano v: | Adv Ther |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer Healthcare
2020
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7467434/ https://ncbi.nlm.nih.gov/pubmed/32445184 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-020-01366-2 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|